Genome sequencing leadership Position 454 Life Sciences as a pioneer in early high-throughput sequencing with the Genome Sequencer system. Target buyers in academic and biotech labs seeking established, long-read capability and robust de novo sequencing workflows.

Sustainability pedigree Leverage Roche’s sustainability recognition to engage risk-averse procurement teams and enterprise accounts prioritizing ESG criteria, offering a narrative that aligns sequencing technology with responsible science and corporate stewardship.

Strategic leadership Highlight recent executive appointments and Roche Diagnostics integration to buyers evaluating stability and strategic direction. Use that momentum to pursue multi-year platform adoption deals and scalable service/support arrangements.

Clinical and research breadth Capitalize on applications spanning cancer, infectious disease, metagenomics, and RNA analysis to cross-sell ancillary reagents, software, and analytics services that complement sequencing workflows across departments and institutions.

Mid-market monetization Target mid-sized biotechs and academic labs with revenue in the lower to mid hundreds of millions range, offering value-based bundles, training, and maintenance plans that fit their scale while expanding genome sequencing coverage.